Abstract:Management of moderate to severe pain relies heavily on opioid analgesics such as morphine, oxycodone, and fentanyl in clinics. However, their prolonged use was associated with undesirable side effects. Many new strategies to reduce side effects have been proposed, but not without disadvantages. Using a hot plate model as a phenotypic screening method, our studies identified (3R,4S)-9d with a new scaffold as a potent analgesic with ED50 values of 0.54 mg/kg and 0.021 mg/kg in hot plate and antiwrithing models, respectively. Mechanistic studies showed that it elicited its analgesic effect via the active metabolite (3R,4S)-10a. The mechanism of (3R,4S)-10a-induced activation of the μ opioid receptor (MOR) was proposed by means of molecular dynamics (MD) simulation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00722?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00722</a>.Active murine MOR, PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00722/suppl_file/jm1c00722_si_001.pdb">PDB</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00722/suppl_file/jm1c00722_si_002.csv">CSV</a>)Screening of resolution of 4c; optimization of the resolution procedure of 4c; HPLC spectrum of 4c and its enantiomers; experimental and theoretical ECD; In vivo metabolism assay; potential energy and RMSD evolution during MD simulation; 1H NMR and 13C NMR spectra of final compounds; HPLC spectra of key compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00722/suppl_file/jm1c00722_si_003.pdf">PDF</a>)This article has not yet been cited by other publications.

Discovery of a highly selective and potent kappa opioid receptor agonist from N-cyclopropylmethyl-7α-phenyl-6,14-endoethano-tetrahydro- northebaines with reduced central nervous system (CNS) side effects navigated by the message-address concept.

Discovery of an Ortho-Substituted N -Cyclopropylmethyl-7α-phenyl-6,14- endo ethano-tetrahydronorthebaine Derivative as a Selective and Potent Kappa Opioid Receptor Agonist with Subsided Sedative Effect

Discovery of an Ortho-Substituted N-Cyclopropylmethyl-7α-phenyl-6,14-endoethano-tetrahydronorthebaine Derivative As a Selective and Potent Kappa Opioid Receptor Agonist with Subsided Sedative Effect

Discovery of an M -Substituted N -Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaine as a Selective, Potent, and Orally Active κ-Opioid Receptor Agonist with an Improved Central Nervous System Safety Profile

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

Discovery of N′-benzyl-3-chloro-N-((1S,3R,4R)-3-((dimethylamino) Methyl)-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl)benzenesulfonamide As a Novel Selective KOR Ligand

Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

Design, Syntheses, and Pharmacological Characterization of 17-Cyclopropylmethyl-3,14 Beta-Dihydroxy-4,5 Alpha-Epoxy-6 Alpha-(Isoquinoline-3 '-Carboxamido)morphinan Analogues As Opioid Receptor Ligands

Design, Synthesis, and Biological Evaluation of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan Derivatives As Peripheral Selective Μ Opioid Receptor Agents.

Novel selective κ agonists SLL-039 and SLL-1206 produce potent antinociception with fewer sedation and aversion

Discovery of 3-((Dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-n-phenylpiperidine-1-carboxamide As Novel Potent Analgesic.

The Pharmacological Heterogeneity of Nepenthone Analogs in Conferring Highly Selective and Potent Κ-Opioid Agonistic Activities.

Discovery, Structure-Activity Relationship, and Mechanistic Studies of 1-((3R,4s)-3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)piperidin-1-yl)-2-(2,4,5-trifluorophenyl)ethan-1-one As a Novel Potent Analgesic.

Design, synthesis, and biological evaluation of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective Antagonists

SLL-627 Is a Highly Selective and Potent κ Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity

Discovery, Structure–Activity Relationship, and Mechanistic Studies of 1-((3 R ,4 S )-3-((Dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)piperidin-1-yl)-2-(2,4,5-trifluorophenyl)ethan-1-one as a Novel Potent Analgesic

Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Pharmacological Characterization of 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) As a Dual Selective MOR/KOR Ligand with Potential Applications in Treating Opioid Use Disorder.

Design, Synthesis, and Structure–Activity Relationship Exploration of Alkyl/Phenylalkyl Piperidine Analogues As Novel Highly Potent and Selective Μ Opioid Receptor Agonists

Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability Via a Complementary Structure-Activity Relationship Study on Nalfurafine Analogues

Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.